Recent research shows that obesity is associated with changed bowel flora composition with a relative abundance of the two dominant bacterial divisions, the Bacteroidetes and the Firmicutes. Interestingly, this specific bacteria associated condition…
insulin resistance, obesity, gut microbiota, SCFA
Onderzoeksproduct en/of interventie
The primary endpoint is changes in weight in relation to fecal flora composition and short chain fatty acid metabolism in fecal samples after 3, 6, 12 and 18 weeks.
Achtergrond van het onderzoek
To investigate whether single vs multiple doses of fecal therapy by infusion of allogenic (lean donor feces in the bowel) or autologous (own feces) have differential effect on longterm reduction of insulin resistance, postprandrial dyslipidemia and short chain free fatty acid metabolism.
Double blind randomized controlled single center trial.
Male obese patients with metabolic syndrome.
Patients will be randomised to one of the three treatment arms: Single (baseline) or multiple (at baseline and after 6 weeks) allogenic feces (infusion of lean donor feces by duodenal tube) or single autologous (own) feces at baseline.
The primary endpoint changes in fecal flora composition and shortchain fatty acid metabolism in fecal samples after 3, 6, 12 and 18 weeks. Secondary endpoints are changes in insulin resistance/fatty acid metabolism (assessed by hyperinsulinemic normoglycemic clamp and stable isotope glucose) and postprandrial lipidmetabolism (mixed meal test) at baseline and after 6 and 18 weeks. Finally, changes in gutregulatory hormones in plasma (leptin, adiponectin and GLP-1) will be assessed.
It is estimated that a total of 45 patients (15 MS patients per treatment arm) and 30 healthy lean volunteers are need.
Doel van het onderzoek
Recent research shows that obesity is associated with changed bowel flora composition with a relative abundance of the two dominant bacterial divisions, the Bacteroidetes and the Firmicutes. Interestingly, this specific bacteria associated condition is transmissible: colonization of obese mice with an ‘leanmicrobiota’ results in a significantly greater decrease in total body fat (-30%) than colonization with a ‘obese microbiota’ (+5%). In addition, Bacteroidetes species are decreased and Firmicutes increased in feces of obese people compared to lean people . We recently finished the FATLOSE trial, in which we studied the therapeutic effect of donor feces infusion from screened volunteers after 6 weeks on insulin resistance (hyperisulinemic clamp with stable isotopes) in male patients with metabolic syndrome. We found significant reduction in both periferal and hepatic insulin resistance implicating substantial effects of whole body glucose metabolism. Moreover, we found significant reductions in fasting lipidprofiles after allogenic fecal therapy, which are in line with previously published data suggesting a direct effect between duodenal lipid uptake and glucose production orchestrated by gutmicrobiota driven brain-gut axis. The efficacy of fecal therapy is explained by enhanced production of specific short chain free fatty acid butyrate produced by the infused lean donor feces, which probably restores normal fecal physiology by implantation of missing lean-figure flora components.
Baseline, 3, 6, 12 and 18 weeks.
Onderzoeksproduct en/of interventie
Patients will be randomised to one of the three treatment arms:
Single (baseline) or multiple (at baseline and after 6 weeks) allogenic feces (infusion of lean donor feces by duodenal tube) or single autologous (own) feces at baseline and after 6 weeks.
Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)
1. Male obese subjects with metabolic syndrome (n=45);
2. 21 to 69 years-old;
3. Body mass index (BMI) 30 to 43 kg/m2);
4. At least 3 out of 5 NCEP metabolic syndrome criteria.
Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)
1. Cardiovascular event (MI or pacemaker implantation);
2. Use of medication including PPI and antibiotics;
3. (Expected) prolonged compromised immunity (due to recent cytotoxic chemotherapy or HIV infection with a CD4 count < 240).
In dit register bekende (historische) registraties
Geen registraties gevonden
In overige registers
|Ander register||CCMO : 35474|
|ISRCTN||ISRCTN wordt niet meer aangevraagd.|